College of Medicine, Shihezi University, Shihezi, Xinjiang, China.
College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
PLoS One. 2020 Sep 11;15(9):e0238784. doi: 10.1371/journal.pone.0238784. eCollection 2020.
Apela, a novel endogenous peptide ligand for the G-protein-coupled apelin receptor, was first discovered and identified in human embryonic stem cells in 2013. Apela has showed some biological functions in promoting angiogenesis and inducing vasodilatation of mammals by binding apelin receptor, but little is known about its expression characteristics and regulatory mechanism in chicken. In the present study, the coding sequences of Apela in chicken was cloned. The evolution history and potential function of Apela were analyzed. Subsequently, the spatiotemporal expression characteristics of chicken Apela were investigated. Furthermore, the regulatory mechanism of Apela mRNA responsing to estrogen was explored by in vitro and in vivo experiments. The results showed that the length of the CDs of Apela mRNA was 165 bp and encoded a protein consisting of 54 amino acids residues with a transmembrane domain in chicken. The Apela was derived from the same ancestor of Apelin, and abundantly expressed in liver, kidney and pancreas tissues. The expression levels of Apela in the liver of hens were significantly higher at the peak-laying stage than that at the pre-laying stage (p ≤ 0.05). The Apela mRNA levels were significantly up-regulated in primary hepatocytes treated with 17β-estradiol (p ≤ 0.05), and could be effectively inhibited by estrogen receptor antagonists MPP, ICI 182780 and tamoxifen. It indicated that chicken Apela expression was regulated by estrogen via estrogen receptor α (ERα). In individual levels, both the contents of TG, TC and VLDL-c in serum, and the expression of ApoVLDLII and Apela in liver markedly up-regulated by 17β-estradiol induction at 1mg/kg and 2mg/kg concentrations (p ≤ 0.05). This study lays a foundation for further research on Apela involving in hepatic lipid metabolism.
Apela 是一种新型内源性肽配体,可与 G 蛋白偶联的 Apelin 受体结合,最初于 2013 年在人类胚胎干细胞中被发现和鉴定。Apela 具有促进血管生成和诱导哺乳动物血管扩张等生物学功能,但关于其在鸡中的表达特征和调控机制知之甚少。本研究克隆了鸡 Apela 的编码序列,分析了 Apela 的进化历史和潜在功能,随后研究了鸡 Apela 的时空表达特征,进一步通过体外和体内实验探讨了 Apela mRNA 对雌激素的调控机制。结果表明,鸡 Apela mRNA 的 CDs 长度为 165bp,编码的蛋白由 54 个氨基酸残基组成,具有跨膜结构域。Apela 与 Apelin 具有相同的祖先,在鸡的肝脏、肾脏和胰腺组织中大量表达。母鸡肝脏中 Apela 的表达水平在产蛋高峰期显著高于产蛋前期(p≤0.05)。用 17β-雌二醇处理原代肝细胞后,Apela mRNA 水平显著上调(p≤0.05),雌激素受体拮抗剂 MPP、ICI 182780 和他莫昔芬可有效抑制其表达。表明鸡 Apela 表达受雌激素通过雌激素受体 α(ERα)调控。在个体水平上,17β-雌二醇以 1mg/kg 和 2mg/kg 浓度诱导后,血清中 TG、TC 和 VLDL-c 的含量以及肝脏中 ApoVLDLII 和 Apela 的表达均显著上调(p≤0.05)。本研究为进一步研究 Apela 参与肝脂代谢奠定了基础。